Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals develops clinical-stage therapies centered on Next Generation Cancer (NGC) drug products. Company news commonly covers NGC-Cap, its lead oncology asset combining PCS6422 with capecitabine, including clinical updates in advanced or metastatic breast cancer and disclosures on metabolite exposure, safety profile and therapeutic-index objectives.
Updates also address the company's broader pipeline and business priorities, including PCS499 for focal segmental glomerulosclerosis, partnership activity for non-oncology assets, capital actions, conference participation, governance matters and operating or financial results tied to its development-stage biotechnology model.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is set to present at the World Orphan Drug Congress USA 2022 from August 25-27, 2022. Dr. David Young, CEO, will discuss 'Balancing the Benefit-Risk of an Orphan Drug: Case Studies' on August 25 at 1:30 PM ET. The company's mission focuses on developing treatments for patients with unmet medical needs, showcasing three drugs in clinical development targeting various cancers and other conditions. For more details, visit www.ProcessaPharma.com.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) reported significant advancements in its clinical programs, including the addition of RX-3117 as a fourth asset. Financial results for Q2 2021 show cash reserves of $20.8 million, up from $15.4 million in December 2020. The company announced a net loss of $3.2 million for the quarter, compared to $733,000 in Q2 2020. Key milestones ahead include filing an IND for PCS12852 and interim data for PCS6422 by Q4 2021. Processa targets markets worth $500 million to $1.5 billion with its clinical programs.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) will hold a conference call on August 12, 2021, at 5:30 p.m. EST to discuss second quarter results and updates on its clinical pipeline. The company focuses on developing treatments for patients with high unmet medical needs, currently advancing three drugs: PCS499 for Ulcerative Necrobiosis, PCS3117 for metastatic pancreatic and non-small cell lung cancers, and PCS6422 for metastatic colorectal and breast cancers. An IND for PCS12852 targeting gastroparesis is expected in 3Q2021.
Processa Pharmaceuticals has initiated its Phase 1b clinical trial for PCS6422, targeting patients with advanced, refractory gastrointestinal cancer. The first patient has been dosed in this multicenter study, which aims to assess the safety and pharmacokinetics of PCS6422 in combination with capecitabine. Interim results are expected by the end of 2021, with further studies planned for 2022 to establish maximum tolerated doses and biomarkers. The trial represents a significant step in developing therapies for patients with unmet needs in cancer treatment.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) will present at the "Zooming with LD Micro" virtual investor event on July 29, 2021, at 12:00 PM ET. Investors can register for the event on the company's website. Processa focuses on developing treatments for unmet medical needs and has a team experienced in over 30 FDA drug approvals. The company emphasizes improving patient survival and quality of life through its innovative products.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) will present at the Access to Giving Virtual Conference on July 14, 2021, at 10:30 a.m. ET. The presentation will be led by CEO Dr. David Young. The conference targets a range of companies and facilitates one-on-one meetings with qualified investors, who will donate to participate. Processa focuses on developing treatments for unmet medical needs, supported by a team with extensive FDA approval experience. For registration, visit here.
Processa Pharmaceuticals (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma (NASDAQ: OCUP) for RX-3117, an oral anticancer agent with FDA Orphan Designation for pancreatic cancer. The agreement grants Processa an exclusive worldwide license (excluding China) to develop and commercialize RX-3117. A Phase 2b trial is set to begin in 2022 to evaluate biomarker correlations and clinical effectiveness in patients with pancreatic and non-small cell lung cancer. The program aims to improve treatment options for patients needing better survival rates.
Processa Pharmaceuticals (NASDAQ: PCSA) announced it will join the Russell Microcap Index after the annual reconstitution on June 28, 2021. This inclusion signifies a substantial milestone for the company, potentially enhancing its visibility among investors and providing access to a wider investment base. The Russell indexes are crucial as they benchmark approximately $10.6 trillion in assets, suggesting that Processa's membership could attract more institutional investors. The company focuses on developing therapies for unmet medical needs, emphasizing treatments for various serious conditions.
Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in the LD Micro Virtual Investor Conference, scheduled for June 9, 2021, at 1:30 p.m. ET, Track 4. Management will present details about the company's pipeline aimed at improving survival and quality of life for patients with unmet medical needs. Current programs include PCS6422 for cancer treatments, PCS499 for ulcerative necrobiosis lipoidica, and PCS12852 for gastrointestinal issues. A live audio webcast of the event will be available for attendees.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two upcoming investor conferences. They will attend the Craig-Hallum Virtual Institutional Investor Conference on June 2, focusing on one-on-one meetings. Additionally, they will present at the Jefferies Virtual Healthcare Conference on June 4, from 2:00 to 2:25 PM EST, where one-on-one meetings will also be available. The company is committed to developing products to enhance survival and quality of life for patients with unmet medical needs.